Model-Informed Development of a Cost-Saving Dosing Regimen for Sacituzumab Govitecan-Reference-Cited by-同舟云学术

Model-Informed Development of a Cost-Saving Dosing Regimen for Sacituzumab Govitecan

Published:2024-06-18 Issue:5 Volume:19 Page:789-796
ISSN:1776-2596
Container-title:Targeted Oncology
language:en
Short-container-title:Targ Oncol

Author:

Moes Dirk J. A. R.^ORCID,Hendrikx Jeroen J. M. A.^ORCID,Guchelaar Henk-Jan^ORCID,Mathijssen Ron H. J.^ORCID,Bakker J. L.,Dezentjé Vincent O.,de Rouw Nikki^ORCID,van Erp Nielka P.^ORCID,Smit Egbert F.^ORCID,van den Heuvel Michel M.^ORCID,Munnink Thijs H. Oude^ORCID,van Kats Maartje,Croes Sander^ORCID,Kroep Judith R.^ORCID,Zwaveling Juliette^ORCID,ter Heine Rob^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s11523-024-01075-8.pdf

Reference21 articles.

1. Early Activity With Frontline Sacituzumab Govitecan/Pembro in Metastatic NSCLC [press release]. 2023, September 10. Available from: https://www.gilead.com/news-and-press/press-room/press-releases/2023/9/gileads-phase-2-evoke02-study-of-trodelvy-sacituzumab-govitecanhziy-in-combination-with-keytruda-pembrolizumab-demonstrates-promising-clinica.

2. Rugo HS, Bardia A, Marme F, Cortes J, Schmid P, Loirat D, et al. Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. J Clin Oncol. 2022;40(29):3365–76. https://doi.org/10.1200/JCO.22.01002.

3. Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384(16):1529–41. https://doi.org/10.1056/NEJMoa2028485.

4. Syed YY. Sacituzumab govitecan: first approval. Drugs. 2020;80(10):1019–25. https://doi.org/10.1007/s40265-020-01337-5.

5. NICE says new triple negative advanced breast cancer drug too expensive for NHS use. 2022. Available from: https://www.nice.org.uk/news/article/nice-says-new-triple-negative-advanced-breast-cancer-drug-too-expensive-for-nhs-use.